CHICAGO (Reuters) May 22 –
Healthcare products maker Johnson & Johnson reported new evidence on Wednesday that its sirolimus-coated stent, used to treat stenotic coronary arteries, works significantly better
than present treatments.
Findings from a US trial indicate that in 98% of cases the drug-coated stents maintain patency in the stent-covered section of the artery, J&J said. At the edges of the stents, the restenosis rate was about 9%. The restenosis rate for non-coated stents is usually between
25% and 30%.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!